{"id":"mbm-02","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4297744","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"MBM-02 works by inhibiting the PI3K/AKT pathway, which is involved in cell proliferation and survival. This inhibition leads to the reduction of tumor growth and metastasis. MBM-02 has shown promise in preclinical studies for its potential to treat various types of cancer.","oneSentence":"MBM-02 is a small molecule that targets the PI3K/AKT pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:59:28.210Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT04729595","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.","status":"TERMINATED","sponsor":"Adamis Pharmaceuticals Corporation","startDate":"2021-09-01","conditions":"Covid19","enrollment":248},{"nctId":"NCT05491928","phase":"","title":"Treatment of Metastatic Cancer in Terminally Diagnosed Patients","status":"AVAILABLE","sponsor":"Matrix Biomed, Inc.","startDate":"","conditions":"Metastatic Cancer","enrollment":""},{"nctId":"NCT01324141","phase":"PHASE1","title":"Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-03-18","conditions":"Anal Cancer","enrollment":6},{"nctId":"NCT04876755","phase":"PHASE2","title":"MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer","status":"UNKNOWN","sponsor":"Matrix Biomed, Inc.","startDate":"2021-05-30","conditions":"Prostate Cancer Recurrent, Biochemical Recurrent Prostate Cancer","enrollment":55},{"nctId":"NCT04874506","phase":"PHASE2","title":"MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)","status":"UNKNOWN","sponsor":"Matrix Biomed, Inc.","startDate":"2021-06-01","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":55},{"nctId":"NCT04337099","phase":"","title":"A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer","status":"AVAILABLE","sponsor":"Matrix Biomed, Inc.","startDate":"","conditions":"Prostate Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tempol; 4-hydroxy-tempo; 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl"],"phase":"phase_2","status":"active","brandName":"MBM-02","genericName":"MBM-02","companyName":"Matrix Biomed, Inc.","companyId":"matrix-biomed-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MBM-02 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}